Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
6 "Ji Sun Nam"
Filter
Filter
Article category
Keywords
Publication year
Authors
Response
Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
Soon Ae Kim, Woo Ho Shim, Eun Hae Lee, Young Mi Lee, Sun Hee Beom, Eun Sook Kim, Jeong Seon Yoo, Ji Sun Nam, Min Ho Cho, Jong Suk Park, Chul Woo Ahn, Kyung Rae Kim
Diabetes Metab J. 2011;35(3):300-301.   Published online June 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.3.300
  • 3,373 View
  • 27 Download
  • 1 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study
    Kentaro Watanabe, Susumu Yamaguchi, Yoshinori Kosakai, Tetsuya Ioji, Hisamitsu Ishihara
    Clinical Drug Investigation.2023; 43(12): 927.     CrossRef
Original Articles
Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
Soon Ae Kim, Woo Ho Shim, Eun Hae Lee, Young Mi Lee, Sun Hee Beom, Eun Sook Kim, Jeong Seon Yoo, Ji Sun Nam, Min Ho Cho, Jong Suk Park, Chul Woo Ahn, Kyung Rae Kim
Diabetes Metab J. 2011;35(2):159-165.   Published online April 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.2.159
  • 4,490 View
  • 53 Download
  • 40 Crossref
AbstractAbstract PDFPubReader   
Background

Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. While studies conducted in other countries have indicated the efficacy and safety of using sitagliptin to treat type 2 diabetes mellitus (T2DM), its predictors of effects to sitagliptin are not well understood. Therefore, we evaluated the predictive clinical parameters for the therapeutic benefits of sitagliptin when added to an ongoing metformin or sulfonylurea therapy in Korean T2DM subjects.

Methods

We obtained data from 251 Korean T2DM subjects who had recently started taking sitagliptin as add-on therapy. Exclusion criteria included any insulin use. Changes in HbA1c (ΔHbA1c) and fasting plasma glucose (ΔFPG) were assessed by comparing baseline levels prior to sitagliptin administration to levels 12 and 24 weeks after treatment. Responders were defined as subjects who experienced decrease from baseline of >10% in ΔHbA1c or >20% in ΔFPG levels at 24 weeks.

Results

We classified 81% of the subjects (204 out of 251) as responders. The responder group had a lower mean body mass index (23.70±2.40 vs. 26.00±2.26, P≤0.01) and were younger (58.83±11.57 years vs. 62.87±12.09 years, P=0.03) than the non-responder group.

Conclusion

In Korean T2DM subjects, sitagliptin responders had lower body mass index and were younger compared to non-responders.

Citations

Citations to this article as recorded by  
  • Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
    Colleen Gavigan, Thomas Donner, Christian S. Goebl
    Journal of Diabetes Research.2023; 2023: 1.     CrossRef
  • Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study
    Masato Odawara, Sumiko Aoi, Tomomi Takeshima, Kosuke Iwasaki
    Diabetes Therapy.2021; 12(8): 2165.     CrossRef
  • Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
    A.J. Scheen
    Diabetes & Metabolism.2020; 46(3): 186.     CrossRef
  • Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
    Naoko Tajima, Jun‐ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel
    Journal of Diabetes Investigation.2020; 11(3): 640.     CrossRef
  • Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
    Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks, Ross N. Butler
    Scientific Reports.2019;[Epub]     CrossRef
  • Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
    Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang, Fuu-Jen Tsai
    Oncotarget.2017; 8(11): 18050.     CrossRef
  • Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
    Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda
    Diabetes, Obesity and Metabolism.2017; 19(6): 874.     CrossRef
  • A Practical Review of C-Peptide Testing in Diabetes
    Emma Leighton, Christopher AR Sainsbury, Gregory C. Jones
    Diabetes Therapy.2017; 8(3): 475.     CrossRef
  • Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials
    S. Del Prato, S. Patel, S. Crowe, M. von Eynatten
    Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(10): 886.     CrossRef
  • Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
    Dong-Sung Lee, Eun-Sol Lee, Md. Morshedul Alam, Jun-Hyeog Jang, Ho-Sub Lee, Hyuncheol Oh, Youn-Chul Kim, Zahid Manzoor, Young-Sang Koh, Dae-Gil Kang, Dae Ho Lee
    Metabolism.2016; 65(2): 89.     CrossRef
  • Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis
    Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueying Gao, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
    Expert Opinion on Pharmacotherapy.2016; 17(12): 1591.     CrossRef
  • Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
    Xiaoling Cai, Wenjia Yang, Xueying Gao, Lingli Zhou, Xueyao Han, Linong Ji, Francesco Giorgino
    PLOS ONE.2016; 11(12): e0166625.     CrossRef
  • Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up
    Jong-Ha Baek, Bo Ra Kim, Jeong Woo Hong, Soo Kyoung Kim, Jung Hwa Jung, Jaehoon Jung, Jong Ryeal Hahm
    Kosin Medical Journal.2016; 31(2): 146.     CrossRef
  • Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes
    Ken-ichi Hashimoto, Yukio Horikawa, Jun Takeda
    Diabetology International.2016; 7(2): 133.     CrossRef
  • Anagliptin and sitagliptin as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, active‐controlled, phase III clinical trial with a 28‐week extension
    S.‐M. Jin, S. W. Park, K.‐H. Yoon, K. W. Min, K.‐H. Song, K. S. Park, J.‐Y. Park, I. B. Park, C. H. Chung, S. H. Baik, S. H. Choi, H. W. Lee, I.‐K. Lee, D.‐M. Kim, M.‐K. Lee
    Diabetes, Obesity and Metabolism.2015; 17(5): 511.     CrossRef
  • Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
    Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Endocrinology and Metabolism.2015; 30(1): 84.     CrossRef
  • C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes
    Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh
    Diabetes Research and Clinical Practice.2015; 108(3): 441.     CrossRef
  • Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
    Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
    Diabetes & Metabolism Journal.2015; 39(6): 489.     CrossRef
  • Response to the dipeptidyl peptidase‐4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin‐6 promoter region under a certain level of physical activity
    Mizue Matsui, Yoshihiko Takahashi, Noriko Takebe, Kazuma Takahashi, Kan Nagasawa, Hiroyuki Honma, Tomoyasu Oda, Mitsutaka Ono, Riyuki Nakagawa, Takayoshi Sasai, Hirobumi Togashi, Mari Hangai, Takashi Kajiwara, Haruhito Taneichi, Yasushi Ishigaki, Jo Satoh
    Journal of Diabetes Investigation.2015; 6(2): 173.     CrossRef
  • Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
    Ji Hyun Kim
    Diabetes & Metabolism Journal.2015; 39(4): 304.     CrossRef
  • Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
    Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho
    Diabetes & Metabolism Journal.2015; 39(4): 335.     CrossRef
  • GLP-1: The Oracle for Gastric Bypass?
    Gema Frühbeck, Ruben Nogueiras
    Diabetes.2014; 63(2): 399.     CrossRef
  • Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes
    Takumi Hirata, Kouichi Inukai, Jiro Morimoto, Shigehiro Katayama, Hitoshi Ishida
    Primary Care Diabetes.2014; 8(3): 265.     CrossRef
  • Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes
    Yukihiro Bando, Masayuki Yamada, Keiko Aoki, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji, Daisyu Toya, Nobuyoshi Tanaka
    Diabetology International.2014; 5(4): 229.     CrossRef
  • The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
    Eun Yeong Choe, Yongin Cho, Younjeong Choi, Yujung Yun, Hye Jin Wang, Obin Kwon, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
    Diabetes & Metabolism Journal.2014; 38(3): 211.     CrossRef
  • Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
    Kazuki Murai, Tomoyuki Katsuno, Jun-ichiro Miyagawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Yoshiki Kusunoki, Masayuki Miuchi, Mitsuyoshi Namba
    Drugs in R&D.2014; 14(4): 301.     CrossRef
  • Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI
    Swneke D. Bailey, Changchun Xie, Guillaume Paré, Alexandre Montpetit, Viswanathan Mohan, Salim Yusuf, Hertzel Gerstein, James C. Engert, Sonia S. Anand
    Diabetologia.2014; 57(4): 738.     CrossRef
  • Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride
    Rieko Umayahara, Takako Yonemoto, Chika Kyou, Kae Morishita, Tatsuo Ogawa, Yoshitaka Taguchi, Tatsuhide Inoue
    Endocrine Journal.2014; 61(12): 1163.     CrossRef
  • The clinical utility of C‐peptide measurement in the care of patients with diabetes
    A. G. Jones, A. T. Hattersley
    Diabetic Medicine.2013; 30(7): 803.     CrossRef
  • Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study
    Naotsuka Okayama, Kenro Imaeda, Takashi Kato, Soji Iwase, Hideomi Ohguchi, Takashi Joh, Yoshinari Hayashi, Masaya Akao, Kohei Ogawa, Mayo Hachiya, Rei Hattori, Ryosuke Kimura, Sachie Yasui, Misao Ando, Yasunari Jinno, Nobuo Takahashi, Manabu Shimizu, Nobo
    Diabetology International.2013; 4(3): 179.     CrossRef
  • Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
    Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
    Journal of Korean Medical Science.2013; 28(6): 881.     CrossRef
  • Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes
    Yukihiro Bando, Kazuhide Ishikura, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka
    Diabetology International.2013; 4(4): 251.     CrossRef
  • The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
    Jun Sung Moon, Kyu Chang Won
    Diabetes & Metabolism Journal.2013; 37(1): 36.     CrossRef
  • Factors Influencing Glycemic Control Response of Sitagliptin
    Gun Woo Kim, Jae Hyun Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Eun Ho Ha, Choon Hee Chung
    The Journal of Korean Diabetes.2013; 14(4): 206.     CrossRef
  • Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
    S-I. Harashima, M. Ogura, D. Tanaka, T. Fukushima, Y. Wang, T. Koizumi, M. Aono, Y. Murata, M. Seike, N. Inagaki
    International Journal of Clinical Practice.2012; 66(5): 465.     CrossRef
  • Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
    Soo Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang
    Clinical Endocrinology.2012; 77(2): 215.     CrossRef
  • Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
    Yuji Tajiri, Munehisa Tsuruta, Tsuyoshi Ohki, Tomoko Kato, Yuko Sasaki, Kayo Tanaka, Shusuke Kono, Masayuki Tojikubo, Kentaro Yamada
    Endocrine Journal.2012; 59(3): 197.     CrossRef
  • Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study
    E. S. Hong, A. R. Khang, J. W. Yoon, S. M. Kang, S. H. Choi, K. S. Park, H. C. Jang, H. Shin, G. A. Walford, S. Lim
    Diabetes, Obesity and Metabolism.2012; 14(9): 795.     CrossRef
  • Letter: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
    Jee-Young Oh
    Diabetes & Metabolism Journal.2011; 35(3): 298.     CrossRef
  • Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
    Yun-Mi Jang, Dong-Lim Kim
    Diabetes & Metabolism Journal.2011; 35(2): 117.     CrossRef
In vivo Corneal Confocal Microscopy and Nerve Growth Factor in Diabetic Microvascular Complications.
Ji Sun Nam, Young Jae Cho, Tae Woong Noh, Chul Sik Kim, Jong Suk Park, Min ho Cho, Hai Jin Kim, Ji Eun Yoon, Han Young Jung, Eun Seok Kang, Yu Mie Rhee, Hyung Keun Lee, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
Korean Diabetes J. 2007;31(4):351-361.   Published online July 1, 2007
DOI: https://doi.org/10.4093/jkda.2007.31.4.351
  • 2,604 View
  • 19 Download
AbstractAbstract PDF
BACKGROUND
In vivo corneal confocal microscopy (IVCCM) is being recognized as a non-invasive, early diagnostic tool for diabetic neuropathy, for it provides a clear image of corneal subbasal nerve plexus in detail. Nerve growth factors (NGF) are believed to regulate peripheral and central nervous system, neuronal differentiation, and regeneration of damaged nerves, and their role in diabetic neuropathy is being emphasized these days. Moreover, NGFs and receptors are also expressed in retina and renal mesangial cells, suggesting their possible role in the common pathogenesis of diabetic microvascular complications. We plan to examine corneal structures of diabetic patients and compare IVCCM with conventional tools and analyze their serum and tear NGF levels. METHODS: IVCCM, nerve conduction velocity (NCV), and serum, urine, and tear samplings were done to 42 diabetic patients. From IVCCM, we measured corneal nerve density, branch, and tortuosity, total corneal/epithelial thickness, and the number of endothelial/keratocyte cells, and we checked patients' biochemical profiles and serum and tear NGF levels. RESULTS: Patients with more severe neuropathy had less corneal endothelial cells (3105 +/- 218 vs. 2537 +/- 142 vs. 2350 +/- 73/mm3 vs. 1914 +/- 465/mm3, P = 0.02), higher serum NGF (36 +/- 15 vs. 60 +/- 57.66 vs. 80 +/- 57.63 vs. 109 +/- 60.81 pg/mL, P = 0.39) and tear NGF levels (135.00 +/- 11.94 vs. 304.29 +/- 242.44 vs. 538.50 +/- 251.92 vs. 719.50 +/- 92.63 pg/mL, P = 0.01). There was a positive correlation between neuropathy and corneal nerve tortuosity (r2 = 0.479, P = 0.044) and negative correlation between neuropathy and endothelial cell count (r2 = -0.709, P = 0.002). Interestingly, similar changes were seen in other microvascular complications as well. CONCLUSION: Our results provide a possibility of using novel tools, IVCCM and NGF, as common diagnostic tools for diabetic microvascular complications, but it should be followed by a large population study.
Relation between Cerebral Arterial Pulsatility and Insulin Resistance in Type 2 Diabetic Patients.
Jong Suk Park, Chul Sik Kim, Hai Jin Kim, Ji Sun Nam, Tae Woong Noh, Chul Woo Ahn, Kyung Yul Lee, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
Korean Diabetes J. 2006;30(5):347-354.   Published online September 1, 2006
DOI: https://doi.org/10.4093/jkda.2006.30.5.347
  • 2,216 View
  • 18 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Diabetic patients have a 3-fold risk for cerebrovascular disease compared with nondiabetic controls. The aim of the present study was to investigate the association of insulin resistance with pulsatility index (PI) of cerebral arteries in type 2 diabetic patients. METHODS: We compared a group of 90 patients with stroke free, type 2 diabetes and an age- and sex-matched control group of 45 healthy subjects without diabetes. Diabetic patients were divided into 3 groups according to the ISI (insulin sensitivity index). We evaluated PI of the middle cerebral artery (MCA) by transcranial Doppler ultrasonography (TCD) and insulin resistance determined by short insulin tolerance test. RESULTS: The PI was significantly higher in diabetic patients than that in healthy controls (P < 0.05), and also higher in patients with insulin resistance than that in insulin sensitive diabetic patients (P < 0.05). The PI of the MCA was significantly correlated with age (r= 0.465, P < 0.01), duration of diabetes (r = 0.264, P = 0.025), hypertension (r = 0.285, P = 0.015) and inversely correlated with insulin resistance (r = -0.359, P = 0.030).Multiple regression analysis was performed with PI as a dependent variable and insulin resistance as an independent variable along with known clinical risk factors. Age (beta = 0.393, P < 0.01) and duration of diabetes (beta = 0.274, P = 0.043) exhibited a significant independent contribution to PI. CONCLUSIONS: PI might be useful markers of the detection of diabetic cerebrovascular changes and insulin resistance, measured with short insulin tolerance test, showed correlations with PI, but age and duration of diabetes contributed independently to the variability in the PI.

Citations

Citations to this article as recorded by  
  • Factors Affecting Basilar Artery Pulsatility Index on Transcranial Doppler
    Ho Tae Jeong, Dae Sik Kim, Kun Woo Kang, Yun Teak Nam, Ji Eun Oh, Eun Kyung Cho
    The Korean Journal of Clinical Laboratory Science.2018; 50(4): 477.     CrossRef
Prevalence of Diabetes Mellitus(Fasting Plasma Glucose by the ADA Criteria) and Impaired Fasting Glucose according to Anthropometric Characteristics and Dietary Habits: 1998 National Health and Nutrition Survey.
Chul Sik Kim, Eun Kyong Jeong, Jina Park, Min Ho Cho, Ji Sun Nam, Hai Jin Kim, Jee Hyun Kong, Jong Suk Park, Joo Young Nam, Dol Mi Kim, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee, Chung Mo Nam
Korean Diabetes J. 2005;29(2):151-166.   Published online March 1, 2005
  • 1,080 View
  • 18 Download
AbstractAbstract PDF
BACKGROUND
The study is based on the National Health and Nutrition Examination Survey in Korea(1998). With these data, we want to predict the prevalence of diabetes mellitus(DM) and impaired fasting glucose(IFG), By investigating anthropometric characteristics and dietary intake habits, we also wanted to analyze any significant correlation between those factors and the prevalences of DM and IFG. METHODS: The study group was comprised of 8,166 people, a representative group of Koreans, who had undergone a health check-up and food intake survey among the total 39,331 members of 12,189 families who were surveyed. RESULTS: The final results are as the follows. 1) The peak prevalence of DM was 15.92% among women in their sixties and 18.21% among men in their fifties, and that of IFG was found to be 16.27% of women in their seventies and 14.09% of men in their sixties. 2) When analyzing the eating habits and the prevalences of DM and IFG, we found that women with more glucose intake had a lesser risk of DM, but this was of no statistical significance. 3) In men, age, total cholesterol, triglyceride(TG), and hypertension(HTN) were revealed as meaningful factors and in women, age, TG, and HTN were revealed as meaningful factors. As to the IFG, in females, age and TG were meaningful factors, and in males, age, TG, the waist/hip ratio (WHR), and body mass index (BMI) were meaningful factors. CONCLUSION: Although this study could not demonstrate meaningful correlation between diet habits and DM, the prevalence of IFG and the recent increase in the prevalence of DM in Koreans, owing to alterations in their diet habits, demands further organized group study for a better understanding of their relationship
The Degree of Atherosclerosis and the Metabolic Characteristics according to the Abdominal Obesity in Type 2 Diabetic Patients.
Chul Sik Kim, Jong Suk Park, Joo Young Nam, Jina Park, Min Ho Cho, Ji Sun Nam, Dol Mi Kim, Soo Jee Yoon, Jae Hyun Nam, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
Korean Diabetes J. 2004;28(5):377-391.   Published online October 1, 2004
  • 1,239 View
  • 20 Download
AbstractAbstract PDF
BACKGROUND
Many of the maturity-onset type 2 diabetic patients with hypertension and dyslipidemia in Korea are not associated with obesity. However, these patients are at risk for developing macrovascular complications such as atherosclerosis due to hyperinsulinemia, insulin resistance and abdominal obesity. The aims of this study were to compare the clinical and biochemical differences between the type 2 diabetic patients that are with and without abdominal obesity, and we also wished to investigate the degree of insulin resistance and atherosclerosis in these patients. METHODS: Among 530 type 2 diabetes mellitus (DM) patients, the percentages of under-weight (UW), normal-weight (NW), over-weight (OW) and obese (OB) (BMI <20, 20-25, 25-29.9 and > or =30, respectively) subjects were 8.9%, 62.1%, 25.1% and 3.9%, respectively. To evaluate the severity of their atherosclerosis, the coronary artery calcification (CAC) score was measured by electron beam computed tomography, and the intima-media thickness (IMT) of the common carotid artery and the ankle-brachial pressure index (ABPI) were also measured. The Insulin sensitivity index (ISI) was measured by the plasma glucose disappearance rate (kitt: %/min). RESULTS: 1. There were no differences in age, duration of DM and the HbA1c levels according to BMI for both the men and women, but the waist-hip ratio (WHR) and systolic blood pressure (SBP) were significantly different among each group. Serum triglyceride (TG), HDL-cholesterol (HDL-C), free fatty acid (FFA), fibrinogen, and fasting c-peptide levels, {excluding total cholesterol (TC)}, were also significantly different. The ISI, which is a marker for insulin resistance, as well correlated with the patients' BMI. Subjects having an with ISI above 2.5%/min were considered as having insulin resistance, and 28%, 60%, 68% and 75% of patients in the UW, NW, OW and OB groups, respectively, demonstrated insulin resistance. The visceral fat area/subcutaneous fat area ratio and visceral fat area/thigh muscle area ratio also increased with BMI. 2. The median values of the WHR were 0.95 for the men and 0.91 for the women. There were no significant differences for age, BMI, duration of DM and HbA1c between patients with and without abdominal obesity, but the SBP, TG, HDL-C, FFA, fibrinogen and ISI were significantly different between those two groups. 3. For the OW group as well as the NW group, the carotid IMT, ABPI and CAC scores were significantly different between the patients with and without abdominal obesity. However, there were no differences between the NW group and the OW group. CONCLUSION: In conclusion, those patients with abdominal obesity, regardless of their BMIs, have a higher prevalence for atherosclerosis, dyslipidemia, and hypertension, compared to those patients without abdominal obesity. Therefore, it is important to screen for atherosclerosis and to manage it accordingly, for the patients with insulin resistance or abdominal obesity in order to decrease their risk of developing atherosclerotic events.

Diabetes Metab J : Diabetes & Metabolism Journal